Sep 2026
Dapagliflozin inhibits renal mesangial cell fibrosis by regulating HO-1/TGF-β1/Smad 2/3 axis.
Diabetic kidney disease (DKD), which is driven by multiple metabolic risk factors, can progress to renal fibrosis and ultimately end-stage renal disease, posing a serious threat to patients with diabetes. Dapagliflozin, a competitive inhibitor of sodium-glucose cotransporter 2, has been reported to alleviate kidney dam...
Xiao-Y. Yuan, Yi Song, Jing-Jing Zhang et al.
· European Journal of Pharmaco... · 0 citations